Updating drug information: Australia TGA considers options
This article was originally published in SRA
Australia's Therapeutic Goods Administration is inviting feedback on the various options it is considering to ensure that product information (PI) and consumer medicines information (CMI) leaflets of approved medicines hold the very latest information1,2.
You may also be interested in...
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.